Chatterjee Abhishek, Ramkumar Dipak B, Dawli Tamara B, Nigriny John F, Stotland Mitchell A, Ridgway Emily B
Lebanon, N.H. From the Dartmouth-Hitchcock Medical Center.
Plast Reconstr Surg. 2015 Mar;135(3):682-689. doi: 10.1097/PRS.0000000000000957.
During breast reconstruction using the transverse rectus abdominis myocutaneous (TRAM) flap, the use of mesh for abdominal donor-site closure provides for a technology that potentially offers clinical benefit yet incurs an added cost. The authors' goal was to determine whether it is cost effective to use mesh during abdominal donor-site closure when performing a TRAM flap for breast reconstruction.
A literature review was conducted to identify and collect published hernia and bulge rates at abdominal TRAM flap donor sites closed either primarily or with mesh. A decision tree analysis was performed. Outcome probabilities, costs of complications, and expert utility estimates were populated into the decision tree model to evaluate the cost-utility of using mesh in TRAM abdominal donor-site closure. One-way sensitivity analyses were performed to verify the robustness of the results.
The authors' literature review resulted in 10 articles describing 1195 patients who had TRAM abdominal donor-site closure primarily and 696 patients who had donor-site closure performed with mesh. Pooled hernia/bulge complication rates for these two groups were 7.87 percent and 4.45 percent, respectively. The use of mesh was more clinically effective based on total quality-adjusted life-years gained of 30.53 compared with 30.41 when performing primary fascial closure alone. The incremental additional cost incurred by the mesh arm when running the decision tree model was $693.14. This difference in cost, divided by the difference in clinical efficacy (0.12), results in an incremental cost-utility ratio value of $5776.17 per quality-adjusted life-year gained when using mesh, making it cost effective (when using a willingness-to-pay threshold of $50,000). One-way sensitivity analysis revealed the following: (1) using mesh was a cost effective option, provided that the price of mesh was less than or equal to $5970; (2) mesh was cost effective when its use led to a hernia/bulge rate less than or equal to 7.25 percent; and (3) primary facial closure was cost effective when its use led to a hernia/bulge rate less than or equal to 4.75 percent.
The use of mesh when repairing the abdominal donor site during a pedicled or free TRAM flap breast reconstruction is cost effective compared with primary fascial closure alone.
在使用腹直肌肌皮瓣(TRAM瓣)进行乳房重建时,使用补片闭合腹部供区创口是一项可能具有临床益处但会增加成本的技术。作者的目标是确定在进行TRAM瓣乳房重建时,腹部供区创口闭合使用补片是否具有成本效益。
进行文献综述,以识别和收集已发表的关于主要缝合或使用补片闭合腹部TRAM瓣供区创口后的疝和膨出发生率。进行决策树分析。将结果概率、并发症成本和专家效用估计值输入决策树模型,以评估在TRAM腹部供区创口闭合中使用补片的成本效用。进行单向敏感性分析以验证结果的稳健性。
作者的文献综述得到10篇文章,描述了1195例主要进行TRAM腹部供区创口闭合的患者和696例使用补片进行供区创口闭合的患者。这两组的合并疝/膨出并发症发生率分别为7.87%和4.45%。基于获得的总质量调整生命年,使用补片在临床上更有效,单独进行一期筋膜闭合时为30.41,使用补片时为30.53。运行决策树模型时,补片区产生的额外增量成本为693.14美元。这一成本差异除以临床疗效差异(0.12),得出使用补片时每获得一个质量调整生命年的增量成本效用比价值为5776.17美元,使其具有成本效益(当使用50000美元的支付意愿阈值时)。单向敏感性分析显示如下:(1)如果补片价格小于或等于5970美元,使用补片是一种具有成本效益的选择;(2)当补片的使用导致疝/膨出发生率小于或等于7.25%时,补片具有成本效益;(3)当一期筋膜闭合导致疝/膨出发生率小于或等于4.75%时,一期筋膜闭合具有成本效益。
与单独进行一期筋膜闭合相比,在带蒂或游离TRAM瓣乳房重建过程中修复腹部供区时使用补片具有成本效益。